BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 26606261)

  • 21. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
    Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
    FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
    Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
    Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F; Li X; Zhang L; Cheng L; Li X
    J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
    Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
    Chen ZW; Hu JF; Wang ZW; Liao CY; Kang FP; Lin CF; Huang Y; Huang L; Tian YF; Chen S
    J Exp Clin Cancer Res; 2022 Apr; 41(1):153. PubMed ID: 35459186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
    Delpu Y; Lulka H; Sicard F; Saint-Laurent N; Lopez F; Hanoun N; Buscail L; Cordelier P; Torrisani J
    PLoS One; 2013; 8(1):e55513. PubMed ID: 23383211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
    Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
    J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.